The Food and Drug Administration's Deliberations on Antidepressant Use in Pediatric Patients by Leslie, L. K. et al.
The Food and Drug Administration's
Deliberations on Antidepressant
Use in Pediatric Patients
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Leslie, Laurel K., Thomas B. Newman, P. Joan Chesney, and James
M. Perrin. 2005. “The Food and Drug Administration’s Deliberations
on Antidepressant Use in Pediatric Patients.” PEDIATRICS 116 (1)
(July 1): 195–204. doi:10.1542/peds.2005-0074.
Published Version doi:10.1542/peds.2005-0074
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:30207961
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
The Food and Drug Administration’s Deliberations on
Antidepressant Use in Pediatric Patients
Laurel K. Leslie, MD*, Thomas B. Newman, MD, MPH‡, P. Joan Chesney, MD§, and James M.
Perrin, MD||
* From the Children’s Hospital, Child and Adolescent Services Research Center, San Diego,
California;
‡ Departments of Epidemiology and Biostatistics and Pediatrics, University of California, San
Francisco, California;
§ Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee;
and
|| MGH Center for Child and Adolescent Health Policy, Harvard Medical School, Boston,
Massachusetts.
Abstract
On February 2, 2004, the Food and Drug Administration organized a joint meeting of the Neuro-
Psychopharmacologic Advisory Committee and Pediatric Subcommittee of the Anti-Infective Drugs
Advisory Committee to examine the occurrence of suicidality in clinical trials that investigate the
use of the newer anti-depressant drugs in pediatric patients. Committee members reconvened on
September 13–14, 2004, and concluded that there was a causal link between the newer antidepressants
and pediatric suicidality. This article provides a summary of the Food and Drug Administration
deliberations for the pediatric clinician. We also provide research, regulation, education, and practice
implications for care for children and adolescents who may be eligible for treatment with these
medications.
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On February 2, 2004, the Food and Drug Administration (FDA) organized a joint meeting of
the Neuro-Psychopharmacologic Advisory Committee and Pediatric Subcommittee of the
Anti-Infective Drugs Advisory Committee and expertise consultants to evaluate the safety of
selected antidepressants in children and adolescents. Specifically, these 2 committees were
charged with examining the occurrence of suicidality (suicidal thinking, behavior, or attempts)
in clinical trials that investigate the use of the newer antidepressant drugs in pediatric patients
with major depressive disorder (MDD) and other psychiatric disorders. At the February
meeting, committee members concurred with the FDA’s decision to reanalyze data available
from current pediatric trials, which had been conducted by or in conjunction with
pharmaceutical companies. On September 13–14, 2004, the Neuro-Psychopharmacologic
Advisory Committee and the newly formed Pediatric Advisory Committee and consultants
met again to review these data and advise the FDA on the use of these medications in pediatric
patients. The committee’s conclusion: there was a causal link between the newer
antidepressants and pediatric suicidality. On October 15, 2004, the FDA ordered
pharmaceutical companies to add to antidepressant advertisements, package inserts, and
information sheets developed for patients and clinicians a “black-box” warning (a statement
in prominent, bold-faced type and framed by a black border) regarding pediatric use. By issuing
this warning, the federal drug regulators imposed one of their toughest requirements, short of
banning a medication.
The intense controversy surrounding these antidepressants and the concurrent public media
coverage have spawned widespread discussion regarding the use of antidepressants in pediatric
patients. The question of whether there is a causal link between the newer antidepressants and
suicidality has major consequences. Suicidality is associated with several of the mental health
disorders for which these medications are used, and treatments to protect against this outcome
are desperately needed. However, it is equally important not to indiscriminately give youths
medications that may increase risk for suicidality.
This article provides a summary of the FDA deliberations for the pediatric clinician. We begin
by reviewing the scope of problems that children and adolescents with depression and other
psychiatric disorders face. We then review the role of the FDA in evaluating these medications
in the past decade and summarize the information presented to members of the committees.
We delineate the decisions reached by the FDA committees during their deliberations. Last,
we provide research, regulation, education and practice implications for quality care for
children and adolescents who may be eligible for treatment with these medications.
SCOPE OF THE PROBLEM
Mental Health Needs of Children and Adolescents
Recent estimates of the rates of mental health disorders in pediatric populations are staggering,
suggesting that at least 1 in 10 children and adolescents has mental illness severe enough to
cause some level of impairment.1–5 Taken in the aggregate, mental health disorders are the
most common pediatric disorders that negatively affect quality of life across the domains of
home, school, and peer functioning. Many youths with these disorders go on to display an
inability to function fully as adults, costing society in terms of both human and fiscal resources.
6
Of particular concern are the mood disorders, including MDD, dysthymic disorder (DD) and
bipolar disorder (BPD). These disorders can be identified in youths of all ages but become
increasingly prevalent in adolescence, with cumulative rates of 16% to 22% by late
adolescence.3,5 Although MDD, DD, and BPD can result in serious morbidity, including
interpersonal difficulties, poor social and school performance, family problems, and substance
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abuse, these disorders also carry with them the very real possibility of suicidal ideation,
attempts, and completion. Suicidality is common in youths; data from the Centers for Disease
Control and Prevention’s National Youth Risk Behavior Survey for the year 2003 indicated
that 16.9% of students in grades 9 to 12 had seriously considered suicide and 2.9% had made
an injurious suicide attempt during the 12 months preceding the survey.7 Data from the year
2001 indicate that although rates of suicide completion decreased in the 1990s, suicide was
documented as the third leading cause of death among young people aged 10 to 24 years and
accounted for 6.8% of total deaths in youths aged 10 to 14 years and 11.9% of youths aged 15
to 24.8
The high prevalence rates of the mood disorders and the serious consequences of suicidality
have prompted research regarding possible treatments, including both psychotherapeutic and
psychopharmacologic regimens. In the past decade, studies have provided a growing evidence
base for psychotherapeutic treatments for these disorders, especially cognitive behavioral
therapy (CBT).9 Psychopharmacologic treatments have also been commonly used in the
treatment of mood disorders in youths for a variety of reasons, including child, family, or
provider choice; lack of responsiveness to psychotherapeutic techniques; possible synergism
of combined psychotherapeutic medication treatment strategies; and limited access to
psychotherapeutic services (as a result of provider, insurance, or geographic constraints).
The use of antidepressants in pediatric patients, particularly the selective serotonin reuptake
inhibitors (SSRIs), has rapidly increased in the past decade. Because of their limited
anticholinergic side effects and cardiovascular toxicity, SSRIs offered several therapeutic
advantages over earlier antidepressants.10 In the 1990s, the SSRIs were used increasingly as
first-line treatment for affective disorders in pediatric patients.11–15 Published research
estimated that the rate of antidepressant use in youths aged 18 years and younger was 1.0 per
100 people by 1996.16 More recent analyses, conducted by the FDA Division of Surveillance,
Research & Communication Support on data collected through the IMS Health, National
Prescription Audit Plus and National Disease and Therapeutic Index programs, found that an
estimated 10.8 million prescriptions were dispensed in 2002 for youths aged 1 to 17 years. The
primary pediatric diagnoses associated with the use of the SSRIs and newer antidepressants
were anxiety disorders in children aged 1 to 11 years and mood disorders in adolescents aged
12 to 17 years. More than 60% of the prescriptions for children aged 1 to 11 years and
adolescents aged 12 to 17 years were prescribed by psychiatrists, with 17% of prescriptions
written by pediatricians.17
Status of Drug Testing for Safety and Efficacy in Pediatric Patients
Much of the use of these newer antidepressants occurred “off-label,” without adequate testing
regarding their safety and efficacy in pediatric populations. Off-label usage of many
medications in pediatric populations had always been common and necessary, as most drugs
had not been studied adequately in children. In the 1990s, the extent of off-label usage for
medications such as the SSRIs in pediatric patients became increasingly important. Research
in many clinical areas suggested very real differences in the absorption, distribution,
metabolism, excretion, efficacy, and safety of some medications in children and adolescents
compared with adults.18 Most salient to this paper were a series of published findings from
multiple studies that provided no evidence of efficacy of the typical tricyclic antidepressants
in the pediatric population, despite evidence to the contrary in adults.19–26 The absence of
specific pediatric labeling information potentially exposes pediatric patients to both safety-
and efficacy-related risks. First, if pediatric pharmacokinetic studies are not available and
dosing regimens are extrapolated from adult data, then pediatric patients might experience
potential adverse reactions that would not be expected, either as a result of physiologic
differences between children and adults or as a result of improper dosing. Second, pediatric
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patients might receive ineffective treatment through under-dosing or through treatment with a
less effective medication in the face of insufficient pediatric information about a more effective
drug.27
These concerns led to the passage of several seminal policy initiatives in the 1990s regarding
medications in pediatric populations. On December 13, 1994, the FDA published its Pediatric
Labeling and Extrapolation Regulation (59 FR 64240), with the aim to foster the study of drug
pharmacokinetics, efficacy, and safety in youths.28 The FDA proposed an additional guideline
on August 15, 1997, which required new drugs to have labeling regarding how the medication
could be used safely in pediatric patients. Two months later, on November 21, 1997, Congress
enacted Section 505a of the Food and Drug Administration Modernization Act (FDAMA),
29 further addressing the needs for improved information about drug use in youths. This
legislation included a provision that authorized market exclusivity incentives to manufacturers
who voluntarily conducted and submitted to the FDA safety and efficacy studies in pediatric
patients in concert with FDA guidance documents. The drugs that required such studies would
be decided by the FDA in consultation with pediatric organizations; the SSRIs and other new
antidepressants were included in the list of medications that needed additional studies.30 After
passage of FDAMA, the FDA received 8 pharmaceutical reports investigating the effects of
antidepressants on pediatric patients.
Over the next several years, additional regulations regarding the FDA review process for
pediatric medications were put into place. In 1998, the FDA published the “Pediatric Rule,”
which required that all new applications with new active ingredients, new indications, new
dosage forms, new dosing regimens, or new routes of administration include an assessment of
efficacy in all relevant pediatric subpopulations, unless the sponsoring organization had
obtained a waiver or deferral of pediatric studies.27 In 2002, Congress passed the Best
Pharmaceuticals for Children Act (BPCA),31 which renewed the exclusivity clause, provided
a process for off-patent drug development, required public posting of results, and mandated
reporting of all adverse events for 1 year after exclusivity was granted.28 This was quickly
followed in 2003 by the Pediatric Research Equity Act,32 requiring the study of drugs and
biologics for pediatric populations and creating a new Pediatric Advisory Committee to advise
the FDA.
Why a Focus on the Newer Antidepressants?
As part of the regulatory process, the FDA reviewed studies that were provided by
pharmaceutical companies to identify any adverse effects identified during the medication
trials. The FDA reviewer for the paroxetine study in 2003 noted that events suggestive of
possible suicidality were categorized under the term “emotional lability” rather than under a
phrase more directly suggestive of suicidality, possibly obscuring any results regarding
potentially serious adverse events. This raised concern that additional adverse events might
have been misclassified. After an internal review, the FDA requested that GlaxoSmithKline,
the manufacturer of paroxetine, separate out all terms suggestive of suicidal ideation, attempts,
or completion.
The possibility that these medications could trigger suicidality was not unheard of; similar
concerns had been raised in adults during the early 1990s.33–37 In 1991, the FDA had
assembled an expert panel to probe reports that suggested a causal link between SSRIs and
suicidality in adults. The advisory group concluded that there was insufficient evidence for
causality.38 Questions regarding both the efficacy and the safety of antidepressants in adults,
however, have continued to be raised.39–46 In addition, 2 studies in the literature reported
increased psychiatric adverse effects in children and adolescents who used SSRIs.47,48 One
GlaxoSmithKline-sponsored study did report more psychiatric adverse events with paroxetine
compared with placebo,49 but the article failed to report that the increase was statistically
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significant and claimed that because the clinical investigators did not consider these events to
be related to paroxetine, causality could not be determined.
In response to the FDA request, GlaxoSmithKline conducted a reanalysis of their data. The
revised analyses documented an increased risk for suicidality in pediatric patients who take
paroxetine compared with placebo, which was greater than what would be expected by chance
alone. This report was submitted in May 2003 to the Medicines and Health-care Products
Regulatory Agency (MHRA; the British equivalent to the FDA) in the United Kingdom and
to the FDA. On June 10, 2003, the MHRA ruled that the use of paroxetine by general
practitioners was contraindicated for children under the age of 18. This contraindication,
however, did not prohibit psychiatrists from using these medications if they believed that they
were indicated. Nine days later, the FDA issued a public health advisory, suggesting that
paroxetine should not be used in children and adolescents for the treatment of MDD until the
results of additional analyses became available. The FDA also asked pharmaceutical
manufacturers of 8 other newer antidepressants to review data from their research trials for the
occurrence of suicidality in pediatric patients. These medications included 4 other SSRIs
(fluoxetine, sertraline, fluvoxamine, and citalopram) as well as several of the atypical
antidepressants (bupropion, venlafaxine, nefazodone, and mirtazapine; Table 1).
Several events followed this request. First, Wyeth, the producers of venlafaxine, addressed the
FDA’s mandate by voluntarily changing their labels to discourage use of venlafaxine in
pediatric patients and publishing a Dear Health Care Professional letter in August 22, 2003.
Both the label alteration and the letter reflected increased reports of hostility and suicidality in
pediatric patients who participated in the venlafaxine arm during clinical trials, particularly
those trials of medication in youths who had a diagnosis of MDD. Second, the data that were
available for each of the 8 antidepressants (other than paroxetine) were reviewed by FDA staff;
their studies suggested an increase in the risk for suicidality. Although the increase in suicidality
in many individual trials was not statistically significant, most studies had trends in that
direction and none had confidence intervals that excluded a significant increase in suicidality.
This association prompted the FDA to release an updated public health advisory on October
27, 2003, stating that preliminary data showed an excess of reports of suicidality in the SSRIs
and the related antidepressants but that there was a need for additional data analyses before
anything definitive could be concluded. Last, as the FDA received and reviewed the
pharmaceutical companies’ reports on pediatric suicidality and the newer antidepressants, it
became clear that there was a lack of methodologic uniformity across the drug manufacturers’
responses. Different analyses were performed by each company with respect to ascertaining
all events of potential suicidality in the drug treatment group as well as in control subjects. For
example, 1 company acknowledged that they had excluded cases that were not considered
“treatment emergent.” Another company selected cases on the basis of knowledge of treatment
assignment. Review of excluded cases by another drug sponsor demonstrated substantial
differences in risks for suicidality between the FDA analysis and the analysis submitted by the
sponsor.50
INFORMATION AVAILABLE TO THE ADVISORY COMMITTEE
Because of the nonstandardized use of definitions of suicidality across the studies, the FDA
contracted with experts at Columbia University to develop a standard classification scheme
for reclassifying all adverse events suggestive of suicidality across available studies. In
addition, the Neuro-Psychopharmacologic Advisory Committee and the Pediatric
Subcommittee of the Anti-Infectives Committee were jointly convened to review the data and
provide recommendations to the FDA. Also invited were expert consultants in pediatric and
psychiatric care processes, psychopharmacology, and epidemiology and biostatics. These 2
advisory committees and consultants first met in February 2004 to review preliminary
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information regarding the antidepressants and to approve the FDA’s analytic plan. In
September 2004, the newly formed Pediatric Advisory Committee to the FDA and the Neuro-
Psychopharmacologic Advisory Committee reconvened. Materials that were reviewed by the
committees at this meeting addressed both safety and, to a lesser extent, efficacy of the newer
antidepressants. These materials came primarily from 3 sources: (1) narrative testimonies from
>100 families, health care providers, and representatives from consumer groups; (2) the FDA
reanalyses of the data from the pharmaceutical trials recoded by Columbia University
researchers; and (3) an additional National Institute of Mental Health–funded randomized
clinical trial on the use of fluoxetine in pediatric patients.
Narrative Testimonies
During both the February and the September meetings, committee members heard from family
members, community organizations, and health care professionals regarding the use of newer
antidepressants in pediatric patients. The committee did not view these narratives as evidence
about a causal link between the newer antidepressants and suicidality because case reports of
this nature are subject to both sample and information biases. However, the members did see
the narratives as important to their deliberations in 3 ways. First, the narratives reminded
committee members of the importance of weighing potential harm to families regardless of the
decisions made regarding a causal link between the newer antidepressants and suicidality.
Second, some of the narratives also described hostile acts of violence to others by youths who
took these medications and emphasized the importance of studies to examine these additional
adverse effects of antidepressants.33,48 Third, families described the use of these medications
for indications such as nail biting, insomnia, and migraine headaches as well as lack of follow-
up by prescribing physicians, suggesting that non–evidence-based, casual use of these
medications might be occurring and that this perspective needed to be shared with professional
medical organizations.
Data Classified by Columbia University and Reanalyzed by the FDA
Data from the Columbia Project was also presented to the Advisory Committees. The FDA
had pooled data from 24 studies to provide to the Columbia investigators to examine the
association between suicidality and the newer antidepressants. These studies included
published and unpublished studies conducted by pharmaceutical sponsors for a variety of
mental health indications as well as data from the Treatment for Adolescents with Depression
Study (TADS), a randomized, clinical trial that compared fluoxetine, CBT, and combination
therapy with placebo.51 The FDA contracted with suicide experts at Columbia University to
review all narratives of reports of adverse events from these trials and recode the narratives
with respect to suicidality. Of the 24 studies, only 109 events were classified as pertinent to
the FDA’s question regarding suicidality. It is important to note that there were no cases of
completed suicide in the 24 studies. The FDA then conducted a reliability study on the
Columbia classification and used the recoded narratives in a pooled analysis of the data.
Because many of the studies that were reviewed by the FDA Advisory Committees were
conducted under the FDAMA provisions described above, before implementation of the BPCA
and Pediatric Research Equity Act legislation, it is important to review how this legislation
may have affected the data that were available to both the Columbia and the FDA investigators.
FDAMA required that, if requested by the FDA, manufacturers provide documentation of at
least 1 clinical investigation in pediatric age groups in which the drug’s use was anticipated,
although some group other than the manufacturer could perform the study. In addition, studies
needed to be conducted and filed with the FDA before expiration of an existing exclusivity
period to gain an additional 6 months of exclusivity. However, the FDA did not require the
manufacturer to provide definitive information on pediatric efficacy (ie, the results could be
inconclusive). In addition, exclusivity not only would apply to the product being studied in the
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pediatric population but also would be expanded to cover all formulations, dosage forms, and
indications that contained the same active moiety.52 Companies could have substantial
financial benefit from the exclusivity extension if the drug had a large adult market.
The studies that were provided to the FDA regarding the use of antidepressants in pediatric
patients thus had several limitations. First, because many of these drugs were already in use in
adults, pharmaceutical companies were allowed to estimate study sample size and pediatric
dosages on the basis of studies that were conducted in adults. Pediatric pharmacokinetic studies
were not required. Second, the absence of requirement that the studies demonstrate efficacy
may have provided less incentive to ensure careful management of the studies. These criteria
also may have influenced study design; studies often were short in duration (none was longer
than 16 weeks), with small sample sizes. Committee members were informed by the FDA that
sponsors may have had more incentive to complete studies quickly for new drugs or off-label
drugs rather than to maintain the quality of the study at the level required by the FDA. Fourth,
because the studies were not specifically designed to assess suicidality, most were not powered
adequately. The studies also lacked detailed, methodical instrumentation to capture these
results. Most of the studies did not use specific instruments to identify adverse events such as
suicidality; rather, adverse events were collected using open-ended probes. A recent study by
Greenhill et al.53 showed that the open-ended method is more likely to result in underreported
adverse events. Finally, investigators for the different studies used a variety of exclusionary
criteria, diagnostic mechanisms, data collection methods, and coding strategies, making it
difficult to compare across the studies. For example, only 4 of the 24 studies did an extensive
diagnostic screen at the beginning of the trial to delineate participants’ diagnosis and the
presence of any coexisting conditions. Studies varied as to whether they evaluated a youth for
BPD before inclusion. Only 11 of the 24 studies excluded children when there was a family
history of BPD. Studies varied in their inclusion of youths with a history of suicidality; 5 of
the studies permitted youths who were identified as being at risk for suicide (at baseline), and
16 studies did not exclude youths despite a history of suicidal attempts. Fifteen of the studies
examined the use of the newer antidepressants in MDD; the others studied their use in obsessive
compulsive disorder (4), anxiety disorders (3), and attention-deficit/hyperactivity disorder (1).
54
These limitations make the results of the pooled analyses even more compelling. When all 24
studies were pooled, the rate of possible or definitive suicidality among youths who were
assigned to receive antidepressants was 2.19 times greater compared with youths who were
assigned to the placebo groups (95% confidence interval: 1.50–3.19).55 An excess of
suicidality in 1 group at least this large would occur by chance only 1 time in 20 000 (P = .
00005). Importantly, most of the limitations of the data (small sample size, inadequate power,
wide variations in sample inclusion, and possible misclassification of outcomes) would make
it more, not less, difficult to detect differences between groups in randomized, double-blind
trials, causing falsely low estimates for the relative risk of suicidality and falsely high P values.
56
Members of the 2 committees also realized the importance of weighing the benefit-to-harm
ratio of these medications for use in pediatric patients. Limited information regarding efficacy
was summarized for committee members on the efficacy trials, specifically, that FDA analyses
indicated that only 3 of the 15 trials of the newer antidepressants in youths with depression
found a statistically significant benefit of drug over placebo.55 However, specific analyses
were not shared with committee members, and committee members were not able to determine
efficacy adequately from the brief amount of information provided. Two published meta-
analyses that delineated the limitations and potential biases of the available studies were also
presented. These meta-analyses suggested that the efficacy of the antidepressants in children
and youths was likely to be overestimated, because published trials had more favorable results
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than unpublished trials.57,58 Alternatively, the committees were cautioned that the time
limitations under FDAMA might have subjected the trials to a type II error, ie, missing a finding
when one was present.
One other aspect regarding the FDA analyses bears consideration. There were no completed
acts of suicide in the 24 studies; the causal link demonstrated in the FDA analyses therefore
focused entirely on suicidal ideation and behavior. Analyses were conducted to examine these
2 outcomes as a single construct.
Data From the TADS Study
The committees last examined data from the recent TADS study alluded to above. The TADS
study recruited a volunteer sample of 439 patients who were between the ages of 12 and 17
years and had a diagnosis of MDD. Patients were randomized to 4 treatment arms: (1)
fluoxetine alone, (2) CBT alone, (3) CBT with fluoxetine, and (4) placebo. Youths in all 4 arms
of the study, including placebo, improved significantly on the primary outcome, the Children’s
Depression Rating Scale–Revised, although fluoxetine with CBT was the only treatment arm
that showed statistical significance compared with placebo. On some of the other outcome
measures, planned pairwise contrasts indicated that the combination treatment and fluoxetine
alone were superior to placebo, whereas CBT was not. Thus, although there was evidence for
the efficacy of treatment with fluoxetine alone or in combination with CBT in the TADS study,
the high placebo response rate indicates why families and clinicians believe that these
medications are effective, even if 85% of the benefits observed also would have occurred with
placebo.
Suicidal ideation was present in 29% of the TADS sample at baseline, despite the exclusion
of youths who were at high risk for suicidality. Ultimately, suicidality improved significantly
in all 4 treatment arms. Suicide attempts were rare (1.6%), and there were no completed
suicides. The only statistically significant adverse finding was an odds ratio of 2.19 (1.03–
4.62) for harm-related adverse events in youths who were taking fluoxetine compared with
youths who were not taking fluoxetine. Data from the TADS study also suggested a possible
protective effect of CBT against suicidality when used in combination with fluoxetine.
CONCLUSIONS OF THE FDA ADVISORY COMMITTEES AND CONSULTANTS
Members reached the following 4 conclusions. First, the reclassification of adverse events
conducted under the direction of Columbia University as described to the committee members
seemed to have been conducted appropriately with sufficient scientific rigor to decrease biases
inherent in previous classification schemas and to draw conclusions, despite serious limitations
of the available data. Second, analyses that were conducted using the reclassified data
demonstrated that there was an increased risk for suicidality causally related to use of the SSRIs
and related antidepressants. Third, although the data in aggregate supported the finding of
increased suicidality, the studies were too underpowered to draw any conclusions regarding
safety for specific antidepressant agents or for specific disorders. The committees also
considered whether to include “older” antidepressants, although the committees had not
specifically reviewed data on these drugs. Monoamine oxidase inhibitors and tricyclics had
even less evidence for efficacy than the SSRIs and the newer atypical antidepressants and high
risks (especially the possibility of suicide from overdoses). The committees decided to
recommend to the FDA that all antidepressants, both current and future products, have language
added to their label regarding the risk for suicidality.
Finally, the committee addressed the issue of whether the FDA should strengthen the existing
warning on the label of antidepressants or pursue a more aggressive course by applying a black-
box warning for antidepressants. Black-box warnings are used to signal an extremely serious
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risk and have implications for the public marketing of drugs with this type of warning.
Committee members were in agreement that warnings on antidepressants needed to have
sufficiently strong wording to provide adequate protection to the public. Many committee
members and public speakers expressed concerns that the black-box warning might decrease
access to treatment for some youths, if the warning made non-psychiatrists reluctant to
prescribe the drugs. Members cited the current limited number of child and adolescent
psychiatrists and the small numbers projected for the next decade.59 In addition, many
members commented on the difficulties encountered in gaining access to psychotherapeutic
mental health services for some pediatric subpopulations, including inner-city underserved,
underinsured youths and youths who reside in rural communities.
The final vote was in favor of the black-box warning. Committee members also urged the FDA
to develop an antidepressant MedGuide, patient educational material to be included with
medications that are distributed by pharmacists when an antidepressant prescription is filled
for an adult or a pediatric patient. Members recognized that this strategy would provide families
and caregivers access to education about antidepressants but would not guarantee that the
patient, family, and clinician would discuss the risk/benefit ratio of these medications before
initiation of medication treatment. It should be noted that the committees did not address the
specific wording of the black-box warning.
The committees did not recommend that antide-pressants be contraindicated for pediatric
patients, as had been decided by the MHRA in the United Kingdom. Although a
“contraindication” in the United Kingdom would confine use to patients who are cared for by
subspecialists, a contraindication in the United States signifies that these medications could
not be used in pediatric patients. Committee members were unwilling to ban medications that
in the future may demonstrate efficacy in some patients, given adequately designed research
studies, and did not want to preclude treatment for those patients.
RECOMMENDATIONS
During the deliberations of the committees, many issues regarding the diagnosis and treatment
of children and adolescents with MDD and other mood disorders were raised. Although both
committee members and public speakers individually urged that a number of strategies be taken
to address these issues, no formal recommendations were made by the committees. However,
as members of and consultants to the committees, we propose that a number of follow-up
actions be considered by the appropriate federal agencies, professional organizations, and
health plans. These steps fall into 2 categories: (1) research and regulations and (2) clinical
education and practice.
Research and Regulations
The debate over the newer antidepressants highlights considerable flaws in the current system
of medication testing and approval. The SSRI controversy was quickly followed in the fall of
2004 by other signs and symptoms of a system of regulation and research needing change,
including (1) reports of selective dissemination of data regarding adverse drug reactions with
other medications such as rofecoxib (Vioxx)60 and cerivastatin (removed from the market in
2001),61,62 (2) federal hearings by the Committee on Energy and Commerce regarding the
FDA’s role in protecting the public health and publication and disclosure issues, and (3) the
ongoing lawsuit filed by the New York Attorney General against GlaxoSmithKline claiming
suppression of adverse events information regarding Paxil. Journal editors have also called for
changes in the current system; several journals now require that researchers publicly register
all trials if they plan to pursue publication at a later date. The FDA has asked the Institute of
Medicine to conduct a report on the current system of drug safety assurance and provide the
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FDA with recommendations for change. In addition, the FDA recently announced a plan to
restructure their current drug testing, approval, and monitoring system.63
We advocate a number of changes in the current system and available research:
• Guarantee the FDA sufficient independence, authority, and freedom from political
and economic influence to demand high-quality drug trials. These studies should pass
a peer-review process that ensures use of diagnostic assessments, standardized
measures, and appropriate data collection and coding.
• Develop a mechanism for postmarketing surveillance, whether as part of the FDA or
through a separate agency that does not rely on physicians and pharmaceutical
companies to report voluntarily problems with new drugs after the mandated period
required of the pharmaceutical companies. New drugs may introduce new risks that
are relatively rare and may be not apparent until the medication has been in wide use
after marketing.
• Push for disclosure to the public of all safety and efficacy results found in drug trials,
including those that do not support the hypothesis being tested or that are contrary to
the intended outcome. Provide disclosure of results, in a standardized and
interpretable format, on publicly available clinical trial registries such as the new US
government web site www.clinicaltrials.gov and in other informational sources that
are available to the public and the medical professions.
• Additional study is needed regarding suicidality when these medications are used for
other indications, such as anxiety. Data from existing pharmacologic studies
presented to the FDA as well as available large data sets, such as the data from the
Research Unit on Pediatric Psychopharmacology Anxiety Study Group’s
randomized, clinical trial regarding the efficacy of the SSRIs in childhood anxiety,
could potentially be examined to answer this question more specifically.64
• Encourage long-term studies in larger samples that are more reflective of the target
population to examine better both the efficacy and the safety of the newer
antidepressants. These studies should be conducted across mental health conditions
for which the newer antidepressants are used, including the mood, anxiety, and
obsessive-compulsive disorders. They should examine both hostility and suicidality
as outcomes and consider the role of pharmacogenetic variation. Because of the rarity
of these types of adverse events, studies will probably not be undertaken by individual
pharmaceutical companies and will require substantial fiscal and scientific support
from the National Institutes of Health. There is legal precedent for this action; the
2002 BPCA ruling does authorize several institute funding mechanisms as vehicles
for funding studies of drugs if the manufacturers of those drugs decline to conduct
the requested safety and efficacy studies.
Clinical Education and Practice
One of the major concerns of the committees was the need for access to effective and safe care
for children and adolescents with mental health disorders, provided by thoughtful, well-trained
clinicians. Although the FDA regulates pharmaceutical products, its role should not include
the regulation of the practice of medicine. Nonetheless, the black-box warning developed by
the FDA includes specific language detailing that physicians who prescribe these medications
should closely monitor patients with observation that “would generally include at least weekly
face-to-face contact during the first 4 weeks of treatment” with specific visit intervals specified
after those 4 weeks.65
Leslie et al. Page 10
Pediatrics. Author manuscript; available in PMC 2006 August 18.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Professional organizations, including the American Academy of Pediatrics (AAP) and the
American Academy of Child and Adolescent Psychiatry, have rapidly mobilized internal
working groups to respond to the FDA’s proposed black-box warning. Both organizations are
concerned about the potential access issues for patients and their families, reimbursement under
many health plans, and the medicolegal implications of specified numbers and types of visits.
In addition, both organizations are developing provider and family fact sheets regarding these
medications and recommended practice guidelines. The American Academy of Child and
Adolescent Psychiatry is already fast-tracking revision of their 1998 guidelines on the use of
antidepressants in children and adolescence.66 Similarly, evidence-based guidelines for the
diagnosis and treatment of MDD, DD, obsessive compulsive disorder, and the anxiety disorders
need to be updated.
We see the AAP, the American Academy of Family Physicians, and the National Association
of Pediatric Nurse Practitioners as critical primary care partners in the development of these
guidelines. The scope of pediatric mental health disorders is predicted to continue to grow;
recent evidence compiled by the World Health Organization indicates that, by the year 2020,
these disorders will increase proportionately by >50%, internationally, to become 1 of the 5
most common causes of morbidity, mortality, and disability in children.6 Clearly, out of
necessity, the management of these disorders will continue to fall to primary care clinicians.
Professional organizations will have to balance the need to ensure the provision of high-quality
care with the limited availability of psychiatric providers in certain communities and the
potential medicolegal complications of overly rigid practice pattern standards. We recommend
that these organizations partner with medical education groups and health plans to
• Design practical tools and educational programs to assist the primary care clinician
in the diagnosis, referral, and treatment of these disorders and in the evaluation of risk
factors for suicidal ideation and attempts and ensure that the content of these programs
address practical aspects of care, including risk/benefit ratios of psychotropic
medication treatment, indications for pharmacologic treatment, the use of
psychotherapy both as solo and as adjuvant therapy, the content of informed consent
and discussions regarding risks and benefits, mechanisms for monitoring pediatric
patients for both benefits and side effects from treatment, and the importance of and
mechanisms for reporting adverse events.
• Concurrently, conduct studies to determine the role of primary care clinicians in the
identification and treatment of youths with mood disorders. There is currently a
paucity of research regarding the ability of primary care clinicians to identify correctly
youths with these types of disorders and then partner with other professionals in their
treatment. Similarly, studies regarding feasible and effective follow-up and
monitoring schedules need to be conducted in primary care settings.
• Last, 3 events in winter 2004–2005 that have implications for ongoing medical
education included (1) announcements of previously unreported adverse effects with
other psychotropic medications including atomoxetine (Strattera) and mixed
amphetamine salts (Adderall), (2) the recent publication of several contrasting large-
scale studies that examined the association between suicide attempts and the SSRIs
in adults,40,41,67 and (3) another recently published observational study that found
no association between suicide attempts and the SSRIs in pediatric patients.68 These
events highlight that medical knowledge regarding medications is not static. We need
to remind the medical community, health plan administrators, and the public that
treatment recommendations and practice standards must continue to be reexamined
and updated to incorporate new knowledge as it becomes available.
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CONCLUSIONS
The FDA Commission hearings on the use of antidepressants in youths raised a number of
important issues regarding the safety and the efficacy of the SSRIs and related antidepressant
medications. Furthermore, the investigation brought attention to the needed areas of
improvement in our current system for drug approval and postmarketing surveillance in
pediatric as well as adult populations. It will require strong advocacy, greater oversight, and
cross-organizational partnerships between clinicians, professional organizations, federal
agencies, health plans, and consumers to ensure the provision of safe and efficacious treatments
for children and adolescents with mental health needs.
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